Meng LY, Yang CT, Bao JF, Huang JS. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients.
World J Gastroenterol 2024;
30:3261-3263. [PMID:
39086637 PMCID:
PMC11287400 DOI:
10.3748/wjg.v30.i26.3261]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2024] [Revised: 05/30/2024] [Accepted: 06/21/2024] [Indexed: 07/09/2024] Open
Abstract
This letter to the editor relates to the study entitled "Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study", which was recently published by Peng et al. Hepatitis B virus infection represents a significant health burden worldwide and can lead to cirrhosis and even liver cancer. The antiviral drugs currently used to treat patients with chronic hepatitis B infection still have many side effects, so it is crucial to identify safe and effective drugs to inhibit viral replication.
Collapse